Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength?

Group 1 - TG Therapeutics (TGTX) shares increased by 10.2% to close at $40.84, with a notable trading volume compared to normal sessions, and a total gain of 20.6$313 million [2] - The company is targeting $540 million in sales from Briumvi for the current year based on encouraging sales growth [2] Group 2 - TG Therapeutics is expected to report quarterly earnings of$0.19 per share, reflecting a year-over-year increase of 371.4%, with revenues projected at $117.83 million, up 85.6% from the previous year [3] - The consensus EPS estimate for the quarter has been revised 127.5% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] - TG Therapeutics holds a Zacks Rank of 3 (Hold), while Cue Biopharma, another company in the same industry, has a Zacks Rank of 3 (Hold) as well [4][5]